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Abstract
The tumor necrosis factor (TNF) superfamily protein TNF-like 1A (TL1A) is the ligand for death
receptor 3 (DR3). TL1A is induced on activated dendritic cells (DCs) and its expression has been
linked to human inflammatory bowel disease. To address how TL1A might influence intestinal
inflammation, we generated transgenic mice that constitutively express TL1A on DCs. TL1A
transgenic mice developed striking goblet cell hyperplasia in the ileum that was associated with
elevated interleukin (IL)-13 levels in the small intestine. IL-13- and IL-17-producing small
intestinal lamina propria T cells were increased in TL1A transgenic mice. TL1A also enhanced
regulatory T (Treg) cell turnover in vivo and directly stimulated Treg cell proliferation in vitro.
The presence of TL1A attenuated the ability of Treg cells to suppress conventional T cells, an
effect that required DR3 signaling in either conventional T cells or Treg cells. Our findings
identify mechanisms by which chronic DR3 signaling could promote pathogenesis in
inflammatory bowel disease.
INTRODUCTION
An inappropriate effector T-cell response to the commensal flora is considered to be an
important feature in the pathogenesis of inflammatory bowel disease.1 Effector T-cell
responses directed against the commensal microbiota are normally restrained by regulatory
cells, therefore limiting the potential for an overt inflammatory response.2 In particular,
CD4 + Foxp3 + regulatory T (Treg) cells have a key role in promoting tolerance to the
commensal flora and dietary antigens and are essential in maintaining tolerance to self-
antigens.2,3 Although most CD4 + Foxp3 + Treg cells are thought to originate in the thymus,
inducible Foxp3 + Treg cells can be generated from naive CD4 + T cells in certain
microenvironments, including the gut-associated lymphoid tissue.2 Although
hyporesponsive to T-cell receptor stimulation in vitro,4 Treg cells proliferate and expand in
vivo following exposure to self or pathogen-derived antigens.5-7 In addition to T-cell
receptor signaling, CD28 costimulation has been shown to be important for proliferation of
self-reactive Treg cells, a conclusion supported by in vitro studies using antigen-loaded
dendritic cells (DCs).8 There is also evidence that triggering of other costimulatory
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receptors, including GITR (glucocorticoid-induced TNF receptor),9 OX40,10 and 4-1BB,11
can promote Treg cell expansion, but it remains to be determined if this effect is because of
direct stimulation of Treg cells or is mediated indirectly, for example, by interleukin (IL)-2
produced by activated conventional T cells. In addition, stimulation via OX40 on Treg cells
has been reported to block their suppressive function,12 whereas GITR signaling in
conventional T cells can render them resistant to suppression by Treg cells.13
Death receptor 3 (DR3) is a member of the tumor necrosis factor (TNF) receptor
superfamily that shows the highest homology with TNF receptor-1. Unlike TNF receptor-1,
which is ubiquitously expressed, DR3 is expressed primarily on T cells. DR3 is expressed
constitutively on CD4 + T cells, including Treg cells, and is upregulated by antigen
stimulation.14,15 A stimulatory role for DR3 in CD4 + effector T-cell responses has been
suggested based on in vitro16-19 and more recently in vivo studies.14,15,19 Thus, in mice that
are deficient in DR3 signaling, accumulation of effector CD4 + T cells within the inflamed
target tissue was reduced, and consequently immunopathology associated with experimental
autoimmune encephalomyelitis and allergic lung inflammation was ameliorated.14,15,19 The
TNF-like protein TL1A (TNFSF15) is the ligand for DR3.16 TL1A is expressed following
activation of DCs and monocytes by immune complexes20 or Toll-like receptor (TLR)
ligands.19 In addition, TL1A is upregulated on T-cell receptor-stimulated T cells and on
endothelial cells exposed to IL-1 or TNF-α.14,16,19
TL1A expression is tightly regulated following TLR stimulation in vitro19 and in vivo (this
study). However, sustained expression of TL1A was detected on lamina propria DCs in two
spontaneous mouse models of chronic ileitis,18 and both TL1A and DR3 are upregulated in
human inflammatory bowel disease.21 To address how sustained expression of TL1A could
influence immune responses and inflammation in vivo, we generated transgenic mice that
express TL1A constitutively under the control of the CD11c promoter (CD11c-TL1A tg
mice). These mice developed striking goblet cell hyperplasia in the ileum that was
associated with increased production of IL-13 in the intestinal tissue and an increase in the
frequency of activated/memory CD4 + effector T cells. Surprisingly, TL1A exerted
stimulatory effects on Treg cell turnover, but overall the presence of TL1A attenuated the
ability of Treg cells to suppress conventional T cells. These data reveal novel roles for
TL1A in regulating T cell-mediated immune responses that have implications in the
pathogenesis of inflammatory bowel disease.
RESULTS
Sustained expression of TL1A in CD11c-TL1A tg mice
Previous work has shown that in vitro activation of DCs by the TLR ligands
lipopolysaccharide or soluble tachyzoite antigen from Toxoplasma gondii upregulates TL1A
mRNA.19 To examine the effect of DC activation on the expression of TL1A in vivo, we
injected C57BL/6 mice with various TLR ligands, the dectin-1 agonist curdlan, or agents
that activate DCs via CD40 either directly (anti-CD40 antibody) or indirectly (α-
galactosylceramide). Injection of lipopolysaccharide (TLR4 agonist) or polyinosinic–
polycytidylic acid (TLR3 agonist) induced upregulation of TL1A mRNA with expression
peaking at 4 and 6 h, respectively, and declining rapidly to background levels by 24 h
(Figure 1a). In contrast, injection of unmethylated oligonucleotide CpG (TLR9 agonist),
Pam3CysSerLys4 (TLR2 agonist), agonist anti-CD40 monoclonal antibody (mAb), α-
galactosylceramide, or curdlan did not induce upregulation of TL1A (Figure 1a and not
shown). Thus, TL1A expression in vivo is transient and is induced by a subset of receptors
associated with DC activation. Expression of TL1A was then assessed in CD11c-TL1A tg
mice. In naive transgenic mice, expression of TL1A mRNA in the spleen was approximately
tenfold higher than that detected in naive control littermates (Figure 1a). Thus, the
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magnitude of TL1A mRNA expression in CD11c-TL1A tg mice was comparable to that
seen at the peak of the lipopolysaccharide stimulation response in wild-type mice. TL1A
mRNA was also present in the mesenteric lymph nodes and ilea of CD11c-TL1A tg mice,
although at a lower level than that found in the spleen. Expression of TL1A protein in
spleens from CD11c-TL1A tg mice was detected in scattered cells in the red pulp, in clusters
of cells in and around the marginal zone, and in a few cells in the T-zone, consistent with the
distribution of DCs in this organ (Figure 1b). A higher magnification image showed
colocalization of TL1A with CD11c staining, confirming that the TL1A transgene is
expressed in DCs. In naive non-transgenic mice, expression of TL1A was less intense and
confined to a few cells in the red pulp and T-zone (Figure 1b).
CD11c-TL1A tg mice were fertile, born at expected Mendelian frequencies, and appeared
healthy. Because TL1A expression has been shown to be upregulated in Crohn’s disease and
ulcerative colitis21 and in mouse models of intestinal inflammation,18 we assessed whether
CD11c-TL1A tg mice develop spontaneous intestinal inflammation. Histological
examination of colons from CD11c-TL1A tg mice revealed normal tissue architecture and
lack of inflammation (Figure 2a). Thus, there were no signs of epithelial cell hyperplasia,
increased leukocyte infiltration, goblet cell depletion, or tissue ulceration in the colons of
CD11c-TL1A tg mice. In contrast with the normal appearance of the colon, histological
examination of the small intestine revealed a marked increase (two- to three fold) in the
number of goblet cells in the ilea of CD11c-TL1A tg mice (Figure 2b). Further examination
of sections from the small intestine revealed that there was also an increase in the number of
Paneth cells in the ilea of the transgenic mice (Figure 2c). Thus, constitutive expression of
TL1A promotes goblet cell and Paneth cell hyperplasia in the small intestine but does not
lead to overt intestinal inflammation.
Enhanced T-cell activation in CD11c-TL1A tg mice
The total cellularity of spleens and lymph nodes from CD11c-TL1A tg mice was similar to
that found in littermate control mice (not shown), and CD11c-TL1A tg mice had normal
frequencies of CD4 + and CD8 + T cells, B cells, macrophages, DCs, and natural killer (NK)
cells (Figure 3a). However, there was approximately a 50 % decrease in the frequency of
invariant natural killer T (NKT) cells in CD11c-TL1A tg mice (Figure 3a). To assess the
effect of sustained TL1A expression on T-cell activation, we compared the expression of
activation/memory T-cell markers on CD4 + T cells from transgenic and littermate controls.
For these studies we electronically gated out Treg cells based on expression of Foxp3
(forkhead box P3) in order to examine the effect of TL1A specifically on conventional T
cells. The percentage of CD69 +, CD44high, and CD62Llow CD4 + T cells was significantly
higher in transgenic mice when compared with control mice (Figure 3b), demonstrating that
sustained expression of TL1A results in enhanced activation of conventional CD4 + T cells
that presumably recognize environmental antigens.
Constitutive expression of TL1A leads to a marked induction of IL-13 in the small intestine
Goblet cell and Paneth cell hyperplasia are processes that are associated with elevated T
helper type 2 (Th2) cytokine production.22,23 To assess whether Th2 cytokines are elevated
in CD11c-TL1A tg mice, we analyzed expression of IL-4 and IL-13 transcripts. Expression
of IL-4 was not increased in CD11c-TL1A tg mice; however, we observed a marked
elevation of IL-13 in both the mesenteric lymph nodes (~ 30-fold) and ilea (~ 6-fold) of
CD11c-TL1A tg mice (Figure 4a,). The finding that IL-13, but not IL-4, levels were
elevated is not unexpected, as others have reported that when compared with IL-4, IL-13
production is higher and more prolonged during Th2-polarized immune responses.24,25
Interestingly, no increase in IL-13 transcripts was detected in the colons of CD11c-TL1A tg
mice (Figure 4b). We also assessed whether constitutive TL1A expression influences IL-17
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and interferon-γ (IFN-γ) levels. A relatively modest (approximately five fold), but
statistically significant increase in IL-17 was detected in the mesenteric lymph nodes of
CD11c-TL1A tg mice (Figure 4a). There was also a trend toward higher IL-17 expression in
the ilea of CD11c-TL1A tg mice, but this was not statistically significant (Figure 4b).
Surprisingly, IFN-γ expression did not differ between CD11c-TL1A tg and wild-type mice
(Figure 4a). To address the contribution of CD4 + lamina propria lymphocytes (LPLs) to the
increased expression of IL-13 and IL-17 in CD11c-TL1A tg mice, we isolated LPLs from
the small intestines of transgenic and wild-type mice and assessed their ability to produce
cytokines following stimulation with anti-CD3 and anti-CD28. Intracellular staining of
IL-13, IL-17, and IFN-γ showed relatively modest increases in IL-13- and IL-17-producing
cells among CD4 + LPLs in the small intestines of CD11c-TL1A tg mice (Figure 4c). In
contrast, there was no increase in the frequency of IFN-γ-producing CD4 + LPLs in CD11c-
TL1A tg. These data suggest that activated CD4 + T cells could represent a source for IL-13
and IL-17 in the small intestine of CD11c-TL1A tg mice, but do not exclude other cellular
source for these cytokines.
TL1A promotes Treg cell activation and proliferation
In the course of examining the effect of sustained expression of TL1A on the activation state
of CD4 + T cells, we noticed an increase in the proportion of CD4 + CD25 + T cells in
CD11c-TL1A tg mice (not shown). Because recently activated conventional T cells as well
as Treg cells express CD25, we used expression of the Treg marker, Foxp3, to delineate the
effect of TL1A on Treg cells. The percentage of CD4 + Foxp3 + T cells in secondary
lymphoid organs of CD11c-TL1A tg mice was 1.7-fold higher than that found in control
littermates (Figure 5a). Furthermore, the frequency of Treg cells among small intestinal
CD4 + LPLs was also significantly increased in CD11c-TL1A tg mice (Figure 5b). Treg
cells with a naive phenotype (CD44low CD62Lhigh CD69 −) have been shown to proliferate
and acquire an activated/memory phenotype in the periphery.5 In CD11c-TL1A tg mice,
there was a clear and reproducible increase in the proportion of splenic Treg cells that
expressed the proliferation antigen Ki-67 (Figure 5c). An increase in the Ki-67 antigen in
CD4 + Foxp3 − T cells was also detected (Figure 5c), consistent with the observed increase
in activation of conventional CD4 + T cells in CD11c-TL1A tg mice. We also found that the
frequency of splenic Foxp3 + Treg cells with an activated phenotype was increased in
CD11c-TL1A tg mice (Figure 5c). Together, these data suggest that TL1A promotes the
proliferation of Treg cells. To address whether TL1A stimulates Treg cell proliferation by
acting directly on Treg cells, we examined the ability of soluble recombinant TL1A (Figure
6a) to promote the proliferation of purified Treg cells in vitro. Consistent with previous
studies,4 CD25 + Treg cells did not proliferate in the presence of anti-CD3 mAb; however,
Treg cells were stimulated to proliferate when both anti-CD3 and anti-CD28 mAbs were
present in the culture media (Figure 6b). The addition of TL1A to cultures of anti-CD3-
stimulated CD4 + CD25 + T cells induced their proliferation, and the magnitude of the
TL1A-stimulated response exceeded that observed with anti-CD28 mAb (Figure 6b).
Furthermore, TL1A synergized with anti-CD28 mAb in driving Treg cell proliferation
(Figure 6b). The effect of TL1A was completely abolished when CD4 + CD25 + T cells
were purified from DR3-deficient mice, demonstrating that TL1A mediated its effects
through DR3 (Figure 6b). To exclude the possibility that the effects of TL1A could have
been because of stimulation of a small population of contaminating CD25 + conventional T
cells, we repeated these experiments using highly purified Treg cells from Foxp3–GFP
(green fluorescent protein) knock-in mice.26 that were isolated by cell sorting based on
expression of GFP (Figure 6c). The findings from these experiments confirmed that TL1A
triggers Treg cell proliferation by acting directly on Treg cells (Figure 6d).
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TL1A attenuates suppression by Treg cells
To address whether TL1A costimulation affects the ability of Treg cells to suppress
conventional effector T cells, we co-cultured Treg cells and carboxyfluorescein succinimidyl
ester-labeled conventional T cells in the presence of anti-CD3 with or without soluble
recombinant TL1A. Addition of TL1A allowed conventional T cells to proliferate despite
the presence of Treg cells (Figure 7). This showed that TL1A attenuates suppression by Treg
cells. To address if blockade of suppression by TL1A was the result of DR3 signaling in
conventional effector T cells or Treg cells, we used DR3-deficient and wild-type
conventional or Treg cells in various combinations. Triggering of DR3 on conventional T
cells alone was sufficient to overcome suppression by Treg cells, although less efficiently
than when both conventional T cells and Treg cells expressed DR3 (Figure 7). When
expression of DR3 was restricted to Treg cells, TL1A was also capable of attenuating the
suppressive function of Treg cells (Figure 7). Taken together, these results show that
triggering of DR3 in conventional effector CD4 + T cells and Treg cells contributes to the
ability of TL1A to reverse the suppression exerted by Treg cells.
DISCUSSION
A striking finding of this study is that constitutive expression of TL1A on DCs results in
goblet cell and Paneth cell hyperplasia in the small intestine (Figure 2). Consistent with this
finding, IL-13 was the most prominent cytokine that was elevated in the small intestinal
tissue of CD11c-TL1A tg mice (Figure 4b). IL-13-induced goblet cell and Paneth cell
hyperplasia constitutes a host-defense response that is normally elicited by gastrointestinal
nematodes.22,23,27-29 Besides IL-13, there was a modest increase in IL-17 levels in the
mesenteric lymph nodes of CD11c-TL1A tg mice, but no increase in IFN-γ expression
(Figure 4). The pattern of cytokine expression and the lack of overt intestinal inflammation
in CD11c-TL1A tg micecontrast with the phenotype of transgenic mice that constitutively
express TNF-α or LIGHT, another TNF family protein, where elevated levels of IFN-γ
were associated with severe intestinal immune pathology.30,31 Furthermore, increased levels
of IFN-γ were detected in mice that constitutively express CD70 or GITR ligand, two other
TNF family proteins.9,32 Interestingly, mice that constitutively express OX40 ligand also
have a bias toward overproduction of Th2 cytokines, similar to what we observed in CD11c-
TL1A tg mice, but additionally OX40 ligand transgenic mice spontaneously develop
inflammation in the colon.33 Although currently unclear, the differences between the effects
of TL1A and other TNF family proteins could be because of differences in the cellular
distribution and signaling capacity of the respective receptors. It is noteworthy that
transgenic mice that constitutively express TL1A on T cells also have increased levels of
IL-13 and elevated numbers of goblet cells in the small intestine.34 This demonstrates that
the observed functional effects of TL1A are independent of the cell type that produces
TL1A in vivo. Although TL1A is produced as a type II transmembrane protein, it is also
secreted as soluble protein from activated DCs,20 and therefore it is possible that the effects
of TL1A in CD11c-TL1A tg mice could have been mediated by soluble TL1A released from
DCs.
Constitutive expression of TL1A resulted in increased frequencies of CD4 + T cells with an
effector/memory phenotype (Figure 3b), suggesting that these cells could represent the
source for IL-13 and IL-17 in CD11c-TL1A tg mice. Examination of small intestinal CD4 +
LPLs from CD11c-TL1A tg mice demonstrated that the frequencies of IL-13- and IL-17-
producing CD4 + T cells were both increased when compared with LPLs from wild-type
mice (Figure 4c). However, these increases were relatively small raising the possibility that
the high levels of IL-13 in the small intestinal tissue were derived from another cell type.
Invariant NKT cells that express DR3 could potentially contribute to elevated levels of
IL-13 in the small intestine, as DR3 triggering in vitro was shown to costimulate IL-13
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production by these cells.14 However, we observed fewer invariant NKT cells in CD11c-
TL1A tg mice (Figure 3a), making their contribution to the increased levels of IL-13 in
CD11c-TL1A tg mice unlikely. Generation of CD11c-TL1A tg mice on an invariant NKT
cell-deficient background is required to definitively exclude a role for invariant NKT cells in
this model. Other cell types that may contribute to enhanced IL-13 production in CD11c-
TL1A tg mice include mast cells, basophils, and the recently identified nuocytes and natural
helper cells.35-37 Future studies using IL-13 reporter mice35 may help elucidate other cell
types involved in IL-13 production in CD11c-TL1A tg mice.
The data presented in this study showing that expression of TL1A under steady-state
conditions preferentially increases the frequencies of Th2 and Th17 but not Th1 cells extend
previous findings on the role of the TL1A–DR3 interaction in effector T-cell responses.
Thus, in vitro-generated Th17 cells were shown to express more DR3 when compared with
Th1 and Th2 cells, and this allowed them to be more responsive to TL1A-mediated
costimulation in vitro.15 Furthermore, when CD4 + T cells are cultured under nonpolarizing
conditions, the lack of DR3 signaling was shown to negatively impact the production of Th2
cytokines during the secondary response, but not IFN-γ.14 It should be noted, however, that
in some settings DR3 signaling has been shown to influence IFN-γ-producing cells. Thus, in
experimental autoimmune encephalomyelitis, the absence of TL1A or DR3 resulted in
diminution of not only IL-17 + T cells, but also IFN-γ+ and IL-17/IFN-γ dual expressing T
cells that infiltrate the spinal cord.15,19 Th17 cells can diverge to a Th1 phenotype in
response to IL-12, 38 and therefore it is possible that TL1A could exert effects on IFN-γ
production depending on the balance between Th1- and Th17-promoting cytokines. TL1A
and DR3 are expressed in ulcerative colitis and Crohn’s disease lesions,21 in which IL-13
and IL-17/IFN-γ, respectively, are implicated in disease pathogenesis.39,40 Our findings
suggest that the TL1A–DR3 interaction could exacerbate immunopathology in both of these
conditions by either stimulating increased production of IL-13 or promoting Th17 responses.
An unexpected finding that was revealed by analysis of TL1A tg mice is the effect of TL1A
on Treg cells. We demonstrate that triggering of DR3 on Treg cells can enhance their
activation and turnover (Figures 5 and 6). Treg cells expand during the normal course of an
immune response,6,7,41 and their ability to suppress is enhanced after proliferation.42 Our
data suggest that expression of TL1A on DCs could contribute to the expansion of Treg
cells, while at the same time attenuating their suppressive effects on conventional T cells
(Figure 7). This will have the effect of allowing effector T cells to mount a protective
immune response despite the presence of increasing numbers of Treg cells. Because of the
transient nature of TL1A expression, Treg cells will be expected to re-gain their full
suppressive capability relatively quickly and thus dampen the magnitude of the
inflammatory response.6,7,41,43,44 Indeed, Treg cells isolated from CD11c-TL1A tg mice
were highly efficient in suppressing the proliferation of effector T cells in vitro in the
absence of exogenous soluble recombinant TL1A (sTL1A; data not shown). Using DR3-
deficient or DR3-sufficient Treg cells and conventional CD4 + T cells, we were able to
demonstrate that DR3 signaling in both cell types contributes to the ability of TL1A to
overcome suppression (Figure 7). Whether DR3 exerts these effects through mechanisms
that are shared with OX40, GITR, or IL-6, which have also been reported to reverse
suppression,45 remains to be determined in future studies.
METHODS
Mice, reagents, and analysis of gene expression
To generate CD11c-TL1A tg mice, a DNA fragment containing the coding sequence of
TL1A was cloned into the EcoRI site of CD11c.pDOI-5.46 A NotI/Xho I digested fragment
lacking vector sequences was microinjected into the male pronuclei of FVB/N zygotes.
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CD11c-TL1A tg mice were identified by PCR of genomic DNA using the following
primers: 5′-CTCACCTCCCAGAGGCAAG-3′ and 5′-
GGAGTCTGGCTTGTTTGGTCG-3′. Mice were backcrossed to the C57BL/6 strain for
four to five generations. Transgenic mice and age-matched littermate controls were used at
6–24 weeks of age. sTL1A consisting of the extracellular domain of TL1A fused to the C-
terminus of a rat CD4 domains 3 and 4 tag was produced in Chinese hamster ovary cells and
purified by immunoaffinity column chromatography.47 Expression of TL1A, IL-17, IL-13,
IL-4, and IFN-γ was determined by quantitative RT-PCR using TaqMan gene expression
assays Mm00770031_m1, Mm00439619_m1, Mm00434204_m1, Mm00445260_m1, and
Mm00801778_m1, respectively (Applied Biosystems, Warrington, UK). Fold expression of
TL1A was calculated using the 2 − Δ Δ Ct method and hypoxanthine-guanine
phosphoribosyltransferase (TaqMan assay Mm00446968_m1) or β2-microglobulin
(TaqMan assay Mm00437762_m1) as a reference gene. For relative expression analysis of
cytokine genes, we first normalized the measurement to expression of a reference gene
(ΔCt) and then used 2 − ΔCt to obtain gene expression levels. Gene expression levels were
then normalized to the average gene expression in wild-type mice. DR3-deficient and
Foxp3–GFP knock-in mice were described previously.26,48 Animal experiments were
carried out according to the UK Home Office license guidelines and approved by the
University of Southampton’s ethical committee.
Immunofluorescence confocal microscopy
Frozen sections (10 μm) were fixed in acetone, blocked with 5% normal goat serum, and
incubated with rat (IgG) anti-TL1A (Tan2.2; ref.49) and hamster anti-CD11c (clone N418)
followed by Alexa Fluor 546-conjugated goat anti-rat IgG and Alexa Fluor 488-conjugated
goat anti-hamster IgG (Invitrogen, Paisley, UK). Sections were washed with phosphate-
buffered saline and incubated with rabbit anti-CD3 (Abcam, Cambridge, UK) followed by
Alexa Fluor 647-conjugated goat anti-rabbit IgG (Molecular Probes). Sections were
mounted in Vectashield (Vector Laboratories, Burlingham, CA) and images collected
sequentially on a Leica (Milton Keynes, UK) SP5 CLSM using Argon(488 nm), GreNe (543
nm), and HeNe (633 nm) lasers and a pinhole equivalent to 1 Airy disc. Image (TIFF) files
were transferred to Adobe Photoshop (Adobe Systems Europe, Uxbridge, UK) and contrast
stretched to use the whole gray scale.
Histology
Tissue was fixed in 10% neutral buffered formalin (Sigma, Poole, UK). Samples were
embedded, sectioned, and stained with hematoxylin and eosin.
Isolation of LPLs
After washing with phosphate-buffered saline, small intestinal specimens were incubated in
RPMI media containing 20 mM HEPES, antibiotics, 3% fetal calf serum, 5mM EDTA, and
0.145 mg ml−1 dithiothreitol for 20 min at 37°C with stirring. The tissue was then placed in
media with antibiotics and 2 mM EDTA and agitated for 30 s. This procedure was repeated
three more times before tissue digestion was performed for 15 min at 37 °C in RPMI media
containing 20 mM HEPES, Liberase DL (200 μg ml−1), and DNAse I (0.5 mg ml−1). Fresh
media containing enzymes was then added and intestinal tissue was digested for a further 15
min. The tissue was then mashed and the released cells passed sequentially through 100, 70,
and finally 40 μm cell strainers.
T-cell proliferation and suppression assays
CD4 + CD25 + and CD4 + CD25 − cells were purified to ≥95 and ≥98%, respectively, by
magnetic selection (Miltenyi Biotec, Bergisch Gladbach, Germany). Carboxyfluorescein
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succinimidyl ester-labeled CD4 + CD25 − cells (1.25×105 per well) were cultured with Treg
cells in the presence of irradiated DR3-deficient antigen-presenting cells (2.5×105 per well;
3000 rad) and anti-CD3 (145.2C11, 2 μg ml−1) or anti-CD3 and sTL1A (5 μg ml−1). The
costimulatory effect of sTL1A on Treg cell proliferation was evaluated at 72 h by 3H-
thymidine incorporation following stimulation with anti-CD3 or anti-CD3 and anti-CD28
(37.51, 5 μg ml−1)with or without sTL1A. For these assays, magnetically selected CD4 +
CD25 + T cells (2.5×104 cells per well) or flow-sorted Foxp3 + GFP + Treg cells (FACSAria
II, ≥99 % pure, BD Biosciences, Oxford, UK) were cultured in U-shaped 96-well plates with
irradiated DR3-deficient splenocytes (5×104 per well).
Flow cytometry
Intracellular Foxp3 and Ki-67 staining was carried out using mAbs from eBioscience
(Hatfield, UK) and BD Biosciences (Oxford, UK), respectively, and fixation/
permeabilization reagents from eBioscience. For intracellular cytokine staining, cells (3×106
per ml) were stimulated for 16 h with anti-CD3 (2 μg ml−1) and anti-CD28 (5 μg ml−1).
Brefeldin A (GolgiPlug, BD Biosciences, Oxford, UK) was added to the culture media for
the last 4 h and cells were then stained for IL-17 (TC11-18H10.1), IFN-γ (XMG1.2), or
IL-13 (eBio13A) using the Cytofix/Cytoperm kit from BD Pharmingen. CD1d tetramer was
from Proimmune (Oxford, UK).
Statistical analysis
Errorbars representthe s.e.m. Statistical significance was assessed using a two-tailed
Student’s t-test or Mann–Whitney test in the case of cytokine gene expression data using the
GraphPad Prism software La Jolla, CA.
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Figure 1.
Kinetics of TL1A expression following Toll-like receptor 3/4 (TLR3/4) triggering in vivo
and expression levels in CD11c-TL1A transgenic (tg) mice. (a) Expression of TL1A
transcripts in the spleens of 8–12-week-old tg CD11c-TL1A mice relative to that of wild-
type (wt) mice as determined by quantitative reverse transcriptase-PCR (RT-PCR; solid bar)
and kinetics of expression in wt mice after injection of lipopolysaccharide (LPS; 40 μg),
polyinosinic–polycytidylic acid (pIC; 50 μg), or anti-CD40 monoclonal antibody (mAb; 500
μg). TL1A expression was not upregulated by administration of anti-CD40 mAb (data
points represent the mean fold change of 3 mice per treatment per time point ± s.e. Fold
change was calculated from triplicate quantitative PCR samples). (b) TL1A protein
expression in wt and tg mice. Frozen wt and tg spleen sections were labeled with anti-mouse
TL1A (red) and counterstained with anti-CD3 (blue) and anti-CD11c (green). The lower
panel is a higher magnification image of TL1A-expressing cells in the red pulp and at the
edge of the T-zone. TL1A expression colocalizes with CD11c staining (lower panel;
orange). Bars = 200 μm (top panels) and 50 μm (lower panel).
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Figure 2.
Sustained expression of TL1A leads to goblet cell and Paneth cell hyperplasia in the small
intestine. Representative (n = 10) photomicrographs (original magnification ×100) of
sections from the colon (a) and ileum (b) of a 24-week-old CD11c-TL1A transgenic (tg) or
wild-type (wt) mouse. (c) High-magnification (×400) photomicrographs of granule-rich
Paneth cells from the ileum of a CD11c-TL1A tg or wt mouse. Paraffin sections stained with
hematoxylin and eosin (H&E). The numbers of goblet cells/villus and Paneth cells/crypt
were determined by examining 60 individual villi and crypts from 6 CD11c-TL1A tg or wt
mice.
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Figure 3.
Frequencies of leukocyte subsets in CD11c-TL1A transgenic (tg) mice and activation status
of CD4 + T cells. (a) Representative (n = 5) flow cytometric plots of spleen cells from tg or
wild-type (wt) mice demonstrating similar frequencies of CD4 + T cells, CD8 + T cells,
macrophages (CD11b +), dendritic cells (CD11c high), B cells (CD19 +), and natural killer
(NK) cells (NK1.1 + CD3 −) in tg and wt mice. However, fewer invariant natural killer T
(NKT) cells (NK1.1 + CD3 + or CD1d/α-galactosylceramide (αGalCer) tetramer +) were
present in CD11c-TL1A tg mice. (b) Representative flow cytometric plots showing
expression of activation/memory markers on peripheral CD4 + Foxp3 − cells from wt and tg
mice (7–13-week-old mice; the data shown are representative of five mice per group).
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Figure 4.
Increased spontaneous expression of interleukin (IL)-13 and IL-17 in CD11c-TL1A
transgenic (tg) mice. (a) Relative mRNA expression of IL-13, IL-17, interferon-γ (IFN-γ),
and IL-4 in mesenteric lymph node (mLN) cells of CD11c-TL1A tg and wild-type (wt) mice
(7–24 weeks old) as determined by quantitative real-time PCR. (b) Relative mRNA
expression of IL-13 and IL-17 in intestinal tissues of CD11c-TL1A tg and wt mice as
determined by quantitative real-time PCR. Each data point represents the relative cytokine
expression value of an individual mouse. Relative expression values were calculated from
triplicate quantitative PCR samples. (c) Expression of IL-13, IL-17, and IFN-γ by re-
stimulated CD4 + lamina propria lymphocytes (LPLs) isolated from the small intestine of
CD11c-TL1A tg and wt mice. Each data point represents cytokine expression in cells
isolated from an individual mouse.
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Figure 5.
Increased numbers and enhanced activation of regulatory T (Treg) cells in CD11c-TL1A
transgenic (tg) mice. Bar graph representation of the frequency of Foxp3 + Treg cells in the
(a) spleen and (b) small intestine of CD11c-TL1A tg and wild-type (wt) littermate control
mice (6–13 weeks old; n = 6–8 mice per group). (c) Increased turnover of Treg cells in
CD11c-TL1A tg mice as defined by the frequency of proliferating (Ki-67 +) peripheral
CD4 + Foxp3 + cells in tg and wt mice (8 weeks old; n = 3 mice per group). (d) Flow
cytometric plots of activation/memory markers on electronically gated splenic CD4 +
Foxp3 + cells from 8-week-old tg vs. wt littermate mice. Data are representative of six
independent experiments using 6–13-week-old mice.
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Figure 6.
TL1A directly costimulates regulatory T (Treg) cell proliferation. (a) Sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of purified soluble
recombinant TL1A (sTL1A) confirms the predicted molecular mass of the recombinant
fusion protein. (b) Wild-type (wt) or death receptor 3 (DR3)-deficient (DR3 KO)
magnetically isolated CD4 + CD25 + T cells (purity ≥95%) were stimulated in the presence
of irradiated DR3 KO antigen-presenting cells (APCs) with anti-CD3 or anti-CD3/CD28.
Where indicated, sTL1A was added and proliferation was determined at 72 h by 3H-
thymidine (3H-TdR) incorporation. (c, d) sTL1A costimulates Foxp3 + Treg cells. (c) Dot-
plots of Foxp3 + Treg cells from Foxp3–GFP knock-in mice pre- and post-cell sorting
(purity ≥99.5%). (d) Foxp3 + Treg cells were stimulated in the presence of irradiated DR3
KO APCs with anti-CD3 or anti-CD3/CD28 and where indicated sTL1A was added. Bars
represent the mean±s.e. of triplicate cultures. The results are representative of two
independent experiments.
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Figure 7.
TL1A attenuates Treg cell-mediated suppression. Conventional effector CD4 + CD25 − T
cells (effector T cells; Teff) and CD4 + CD25 + T cells (regulatory T cells; Treg) were
purified from wild-type (wt) or death receptor 3 (DR3) KO mice. Carboxyfluorescein
succinimidyl ester (CFSE)-labeled wt or DR3 KO Teff were stimulated with anti-CD3 or
anti-CD3 and soluble recombinant TL1A (sTL1A) in the absence or presence of titrated
numbers of either wt or DR3 KO Treg. T-cell cultures also contained irradiated DR3 KO
antigen-presenting cells (APCs). Teff proliferation at 72 h was analyzed by dilution of CFSE.
The percentages of Teff cells that had divided are indicated in each plot. Data shown are
representative of two independent experiments.
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